– Collaboration combines Abbott′s world-leading glucose sensing technology with Omada Health’s best-in-class, proprietary digital coaching platform to provide personalized, on-the-go care
– As part of Omada’s expanded Type 2 diabetes offering, FreeStyle Libre will be the exclusive CGM delivered directly to participants’ doorsteps – expanding access to the technology for more people with diabetes
Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott’s revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, with Omada Health’s pioneering digital care program, aiming to create a new paradigm for people with Type 2 diabetes. More than 30 million Americans are living with diabetes – with roughly 95% of them living with Type 2 diabetes1 – and many are looking for simple ways to better manage their condition and overall health.
“The mission of Omada Health has always been to empower meaningful, sustainable behavior change for those individuals living with Type 2 diabetes and other chronic conditions,” said Omada co-founder and chief executive officer Sean Duffy. “Partnering with Abbott to give individuals access to FreeStyle Libre as part of the Omada program will deliver a unique combination of personalized human coaching and technology-enabled care to support those goals.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
With a one-second scan using a smartphone over the FreeStyle Libre sensor worn on the back of the upper arm, users get real-time glucose readings every minute, historical trends and patterns, and arrows showing where glucose levels are going without having to fingerstick.2 The integrated solution with Omada will provide real-time glucose data and actionable information for participants to better manage their diabetes and guide personalized recommendations from their coaches.
“We’ve seen how FreeStyle Libre transforms lives through its proven track record in improving health outcomes, and our goal is to find new ways for even more people with diabetes to benefit from this technology,” said Jared Watkin, senior vice president, Diabetes Care, Abbott. “Through this collaboration, we’re creating a personalized care experience that combines Abbott’s leading CGM technology with Omada Health’s professional coaching and digital platform – giving people with Type 2 diabetes actionable information that leads to better health.”
Source: PR Newswire